After Donor Cell Therapy Approval, Transplant Medicine Faces a New Test of Immune Order
The significance of the FDA’s clearance is not just that it adds another tool for post-transplant care in blood cancer; it pushes the treatment focus toward a more nuanced question: how to let a new immune system develop strength without turning against the patient.